Starting Palliative Care Early Can Improve QoL in Family Caregivers of Cancer Patients

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video we discuss how palliative care early on in the process of treating patients with cancer led to an improvement in depressive symptoms and quality of life among family caregivers.

The involvement of palliative care early on in the process of treating patients with cancer led to an improvement in depressive symptoms and quality of life among family caregivers, according to the results of a study presented by Areej R. El-Jawahri, MD, of the Massachusetts General Hospital in Boston, at the American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago.

Here Dr. El-Jawahri findings from the trial (abstract 10131).

Related Videos
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.
Eric J. Sherman, MD, on the Efficacy of Cabozantinib in Refractory Differentiated Thyroid Cancer
Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center,
Eric J. Sherman, MD, of Memorial Sloan Kettering Cancer Center highlights research on adjuvant capecitabine in nasopharynx cancer.
Related Content
Diagnostic CT-enabled radiation therapy also reduces patient-reported time burden in the palliative setting.

Palliative Diagnostic CT RT Lowers Time in Center Without Harming Efficacy

October 4th 2023
Article

Diagnostic CT-enabled radiation therapy also reduces patient-reported time burden in the palliative setting.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.

mRNA Vaccine/Pembrolizumab Reduces Metastasis/Death Risk in Melanoma

June 7th 2023
Article

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Oncology On-The-Go Podcast: Nursing-Led Palliative Care in Advanced Cancer

May 15th 2023
Podcast

Margaret Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, discusses how nursling-led palliative care may improve advanced cancer care planning uptake based on a secondary analysis of the CONNECT study.

Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma | Image Credit: © David A Litman - stock.adobe.com.

Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma

June 6th 2023
Article

The safety of fianlimab plus cemiplimab appears consistent with the safety profile previously observed with each individual agent among patients with previously treated metastatic melanoma in a phase 1 study.

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.

Sintilimab Combo Reduces Recurrent Disease in Nasopharyngeal Carcinoma

June 6th 2023
Article

Sintilimab plus chemoradiotherapy produces a higher 3-year distant metastasis-free survival rate vs chemoradiotherapy alone among patients with advanced nasopharyngeal carcinoma in the phase 3 CONTINUUM trial.